Ipilimumab

Ipilimumab Uses, Dosage, Side Effects, Food Interaction and all others data.

Ipilimumab is a fully humanized IgG1 monoclonal antibody that blocks cytotoxic T lymphocyte antigen-4 (CTLA-4). Blocking CTLA-4 removes an inhibitory signal from reducing the activity of T lymphocytes. Ipilimumab was developed by Bristol-Myers Squibb and Medarex.

Ipilimumab was granted FDA approval on 25 March 2011.

Ipilimumab is a human IgG1 that binds CTLA-4, preventing 1 T-cell inhibition signal pathway. It has a long duration of action as it is given every 3 to 4 weeks. Patients should be counselled regarding the risk of immune-mediated adverse effects, infusion related reactions, and embryo-fetal toxicity.

Table Of contents

• Ipilimumab
• Uses
• Dosage
• Side Effect
• Precautions
• Interactions
• Uses during Pregnancy
• Uses during Breastfeeding
• Accute Overdose
• Food Interaction
• Half Life
• Volume of Distribution
• Clearance
• Interaction With other Medicine
• Contradiction
• Storage

Trade Name	Ipilimumab
Availability	Prescription only
Generic	Ipilimumab
Ipilimumab Other Names	Ipilimumab
Related Drugs	Opdivo, Yervoy, Keytruda, capecitabine, pembrolizumab, Avastin, bevacizumab, Xeloda, nivolumab, atezolizumab
Weight	5mg/ml,
Type	Intravenous Solution, Intravenous
Formula	C6572H10126N1734O2080S40
Weight	148000.0 Da
Protein binding	Data regarding the protein binding of ipilimumab is not readily available.
Groups	Approved
Therapeutic Class
Manufacturer
Available Country	United States
Last Updated:	September 19, 2023 at 7:00 am

Uses

Ipilimumab is a human cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody used to treat metastatic or unresectable melanoma.

Ipilimumab is indicated to treat unresectable or metastatic melanoma, as an adjuvant in the treatment of cutaneous melanoma, to treat microsatellite-high or mismatch repair deficient metastatic colorectal cancer, or to treat hepatocellular carcinoma. Ipilimumab with nivolumab is indicated to treat advanced renal cell carcinoma.

Ipilimumab is also used to associated treatment for these conditions: Advanced Renal Cell Carcinoma, Cutaneous Melanoma, Hepatocellular Carcinoma, Metastatic Melanoma, Unresectable Melanoma, Metastatic MSI-H/dMMR colorectal cancer

How Ipilimumab works

Cytotoxic T-lymphocyte antigen-4 (CTLA-4) is an inhibitory molecule that competes with the stimulatory CD28 for binding to B7 on antigen presenting cells. CTLA-4 and CD28 are both presented on the surface of T-cells. Ipilimumab is a human IgG1 that binds CTLA-4, preventing the inhibition of T-cell mediated immune responses to tumors.

Toxicity

Data regarding ipilumumab overdose is not readily available. However, the most common adverse reactions to ipilumumab are fatigue, diarrhea, pruritus, rash, and colitis.

Food Interaction

No interactions found.

Ipilimumab Drug Interaction

Major: apixabanModerate: paclitaxel protein-bound, rosuvastatinUnknown: lactobacillus acidophilus, charcoal, amphetamine / dextroamphetamine, doxorubicin, ubiquinone, chondroitin / glucosamine / methylsulfonylmethane, sodium iodide, pembrolizumab, metoprolol, nivolumab, acetaminophen, docusate/senna, multivitamin, cyanocobalamin, cholecalciferol, menaquinone, cetirizine

Ipilimumab Disease Interaction

Major: dermatitis, endocrinopathies, enterocolitis, hepatitis, neuropathies, ocular diseaseModerate: hepatic impairment

Volume of Distribution

The volume of distribution at steady-state of ipilimumab is 7.21L.

Elimination Route

C_max was 65.8µg/mL for 2-6 year olds, 70.1µg/mL for 6-5 Data regarding the AUC and T_max of ipilumumab are not readily available.

Half Life

Ipilimumab has a half life of 14.7 days.

Clearance

Ipilimumab has a clearance of 15.3 mL/hr. Systemic clearance increases proportionally with body weight.

Elimination Route

Data regarding the route of elimination of ipilimumab is not readily available.

Innovators Monograph

You find simplified version here Ipilimumab